ABT · News · 20260930N
Guidance / Outlook
ABBOTT LABORATORIES · 2026-09-30 · Importance 51 · Surprise 60 · In source text
Third-party reporting said Abbott raised its full-year 2026 adjusted EPS guidance to $5.45-$5.60 after reporting second-quarter adjusted EPS of $1.31 and revenue of $12.59 billion. The updated guidance provides management’s forward view for the remainder of 2026 and signals continued confidence despite reported stock-price pressure. Abbott’s next earnings release was scheduled for October 21, 2026, before the market opened. The guidance range is a material outlook item even though the digest did not provide a corresponding revenue or margin forecast.
Key facts
- Abbott raised its full-year 2026 adjusted EPS guidance to USD 5.45-5.60. source
- Abbott will announce its third-quarter 2026 financial results on Wednesday, Oct. 21, before the market opens. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| net_income | positive | probable | — | Abbott raised its full-year 2026 adjusted EPS guidance to USD 5.45-5.60. |